Mark Alles has quickly put together a megaround for his latest venture, and it’s for the most sought-after pocket of oncology R&D: antibody-drug conjugates.
The former Celgene CEO became chief executive of TORL BioTherapeutics three months ago, and on Wednesday the company unveiled a $158 million Series…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
